Is ATAI Life Sciences BV (ATAI) overvalued? · rev $308.0K
ATAI Life Sciences BV (ATAI) is a biotechnology company listed on US.
This page asks whether ATAI Life Sciences BV (ATAI) looks expensive on cached numbers — not a short thesis.
Latest reported ATAI revenue for 2024-12-31 was $308.0K. Net income was -$150.0M. Revenue was down 1.9% from 2023-12-31 to 2024-12-31. ATAI currently screens at market cap $555.8M.
ATAI currently screens at market cap $555.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ATAI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ATAI stock page for the full model, not this heading.
Not investment advice.